Compare Moderna, Inc. (MRNA) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Moderna, Inc. is far larger — about 3.1× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| MRNA | RPRX | |
|---|---|---|
Market Cap | $78.65B | $25.27B |
Volume | 37,373,437 | 3,671,183 |
Sector | Health | Health |
52-Week High | $203.46 | $63.96 |
52-Week Low | $22.36 | $35.44 |
Typical Hold Time | 59 Days | 1 Days |
Enterprise Value | $74.80B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
